BEGIN:VCALENDAR VERSION:2.0 PRODID:-//VLAB - ECPv6.15.19//NONSGML v1.0//EN CALSCALE:GREGORIAN METHOD:PUBLISH X-ORIGINAL-URL:https://staging.vlab.org X-WR-CALDESC:Events for VLAB REFRESH-INTERVAL;VALUE=DURATION:PT1H X-Robots-Tag:noindex X-PUBLISHED-TTL:PT1H BEGIN:VTIMEZONE TZID:America/Los_Angeles BEGIN:DAYLIGHT TZOFFSETFROM:-0800 TZOFFSETTO:-0700 TZNAME:PDT DTSTART:20240310T100000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:-0700 TZOFFSETTO:-0800 TZNAME:PST DTSTART:20241103T090000 END:STANDARD BEGIN:DAYLIGHT TZOFFSETFROM:-0800 TZOFFSETTO:-0700 TZNAME:PDT DTSTART:20250309T100000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:-0700 TZOFFSETTO:-0800 TZNAME:PST DTSTART:20251102T090000 END:STANDARD BEGIN:DAYLIGHT TZOFFSETFROM:-0800 TZOFFSETTO:-0700 TZNAME:PDT DTSTART:20260308T100000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:-0700 TZOFFSETTO:-0800 TZNAME:PST DTSTART:20261101T090000 END:STANDARD END:VTIMEZONE BEGIN:VEVENT DTSTART;TZID=America/Los_Angeles:20250320T183000 DTEND;TZID=America/Los_Angeles:20250320T210000 DTSTAMP:20260409T052731 CREATED:20250213T184800Z LAST-MODIFIED:20250707T213121Z UID:15193-1742495400-1742504400@staging.vlab.org SUMMARY:The Future of Drug Discovery: Is Generative AI the Next Breakthrough in Drug Design? DESCRIPTION:The Future of Drug Discovery\nIs Generative AI the Next Breakthrough in Drug Design?\n \n \n \n \n \n Tuesday\, June 20\, 2006\n6:00 pm to 8:30 pm\n6:00 pm: Reception and networking\n7:00 pm: Panel discussion (with Q&A) \n \n \n \n \n \n \nBuy Tickets on Eventbrite\n\nPurchase Tickets\n\n\n\n\n \n \n \n \n \n \nBuy Tickets on Eventbrite\n\nPurchase Tickets\n\n\n\n\n \n \n \n \n \n New drugs have revolutionized healthcare\, with over 200 novel therapeutics gaining FDA approval over the past five years. One key aspect to product success has been – and will continue to be – finding the right drug to bring into development\, as up to 85% of new synthetic chemical compounds fail to reach the market. Traditionally\, drug candidates have been vetted using a process called high-throughput screening (HTS)\, where thousands of drug candidates are evaluated through their reactivity with specific biological targets. The hit rate of HTS\, however\, can be quite low\, with some estimates at significantly less than 0.01 percent. \nNew Generative AI promises to transform drug discovery through new approaches to identifying drug candidates. By leveraging recent innovations in AI\, companies have mined databases to discover new drug-target interactions or design novel compounds. These revolutionary advances are accelerating the development of treatments for cancers and other complex diseases\, improving patient outcomes and reducing healthcare costs. For both startups and established companies\, this represents an unprecedented opportunity to reshape the future of drug development. \nNew Featuring pharmaceutical executives\, biotech entrepreneurs\, and AI innovators\, our event panel will explore whether AI is truly a breakthrough in drug discovery\, and how it can address long-standing challenges in the industry. \n\nWhat are the key approaches to using Generative AI to invent new drug candidates?\nWhat challenges and limitations remain in AI-driven drug discovery?\nHow can startups navigate FDA evaluation of AI-driven drug discovery approaches?\nHow are pharmaceutical companies and startups collaborating to accelerate AI-driven innovation around drug discoveries?\n\nNew Join us on March 20 to peer into the future of drug discovery. \n \n \n \n \n \n \nBuy Tickets on Eventbrite\n\nPurchase Tickets\n\n\n\n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Moderator \n \n \n \n \n \n \n \n \n \n \n \n AaronArvey\nHead of Computational Discovery\, Third Rock Ventures\n \n \n \n \n \n \n \n \n \n \n LinkedIn\n \n \n \n \n \n \n \n \n \n \n \n \n Panelist \n \n \n \n \n \n \n \n \n \n \n \n PetrinaKamya\nVice President & Global Head of AI Platforms\, Insilico Medicine\n \n \n \n \n \n \n \n \n \n \n LinkedIn\n \n \n \n \n \n \n \n \n \n \n \n \n Panelist \n \n \n \n \n \n \n \n \n \n \n \n VenkateshMysore\nChief Technology Officer and Co-Founder\, Aikium\n \n \n \n \n \n \n \n \n \n \n LinkedIn\n \n \n \n \n \n \n \n \n \n \n \n \n Panelist \n \n \n \n \n \n \n \n \n \n \n \n DavidSolow-Cordero\nAssociate Director\, High Throughput Screening Knowledge Center & Innovative Medicine Accelerator (IMA)\, Stanford University\n \n \n \n \n \n \n \n \n \n \n LinkedIn\n \n \n \n \n \n \n \n \n \n \n \n \n Panelist \n \n \n \n \n \n \n \n \n \n \n \n LuWang\nInvestment Director\, Foothill Ventures\n \n \n \n \n \n \n \n \n \n \n LinkedIn\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Ticket Includes Food and Drink \n \n \n \n \n \n View or download flyer for event: \n \n \n \n \n \n \n \n \n \n \n \n Download printable PDF. \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\n\n\n \n View Page on Eventbrite\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Special Thanks to Our Event Sponsors URL:https://staging.vlab.org/event/future-of-drug-discovery/ LOCATION:SVB Experience Center\, 532 Market Street\, San Francisco\, CA\, 94104\, United States CATEGORIES:VLAB Panel ATTACH;FMTTYPE=image/jpeg:https://staging.vlab.org/wp-content/uploads/2025/01/Future-of-Drug-Discovery.jpg END:VEVENT END:VCALENDAR